[89Zr]girentuximab PET Identifies Any Renal Malignancy with 98% Positive Predictive Value

Redefining the Diagnostic Pathway for Indeterminate Renal Masses

The rising incidence of incidentally detected small renal masses presents a persistent clinical dilemma, as conventional cross-sectional imaging often fails to distinguish between benign lesions and aggressive malignancies [1, 2]. While up to 25% of these masses are eventually found to be benign, the lack of highly specific non-invasive tools frequently leads to unnecessary surgical interventions and associated morbidity [2, 3]. Molecular imaging has emerged as a potential solution to this diagnostic gap, utilizing targeted radiotracers to visualize specific tumor biomarkers like carbonic anhydrase IX and the prostate-specific membrane antigen [4, 5]. Recent advancements in immuno-positron emission tomography (a technique using antibody-based radiotracers to map specific protein expression) have focused on identifying clear cell renal cell carcinoma, the most common and aggressive subtype, by targeting its unique metabolic and surface protein expressions [6, 7]. A new analysis of the ZIRCON trial now provides critical evidence regarding the ability of these targeted tracers to identify a broader spectrum of renal malignancies than previously recognized, potentially shifting the diagnostic focus from a single histological subtype to a more comprehensive assessment of renal cancer.

Molecular Targeting of Carbonic Anhydrase IX

The diagnostic utility of the [89Zr]girentuximab radiotracer rests on its high affinity for carbonic anhydrase IX (CAIX), a cell surface protein that serves as a highly specific biomarker for renal pathology. In the landscape of kidney cancer, carbonic anhydrase IX is expressed in over 90% of clear cell renal cell carcinoma (ccRCC) cases, making it an ideal target for molecular imaging. The overexpression of this protein is fundamentally driven by cellular pathways associated with tumor progression, specifically hypoxia or the loss of the Von-Hippel Lindau (VHL) gene. In the absence of functional VHL protein (a tumor suppressor that normally targets hypoxia-inducible factors for degradation), these factors accumulate and trigger the transcription of CAIX. This process allows the [89Zr]girentuximab positron emission tomography (PET) tracer to visualize malignant tissue at the molecular level by binding to the overexpressed CAIX proteins on the cell surface.

The clinical validation of this approach was established through the phase 3 ZIRCON trial, which prospectively evaluated the performance of [89Zr]girentuximab PET in patients presenting with indeterminate renal masses. The trial successfully met its primary endpoint for the accurate detection of clear cell renal cell carcinoma, demonstrating that the tracer could reliably differentiate this aggressive subtype from other renal lesions. While the initial focus of the ZIRCON trial was the identification of clear cell histology, the underlying mechanism of carbonic anhydrase IX expression in hypoxic environments suggested broader applications. Because various aggressive forms of non-clear cell renal cell carcinoma also exhibit hypoxia-driven CAIX expression, the tracer provides a diagnostic window into a wider array of malignancies than the primary trial results initially emphasized, offering clinicians a more versatile tool for evaluating complex renal presentations.

Expanding Utility to Non-Clear Cell Subtypes

A secondary reanalysis of the ZIRCON trial data indicates that the diagnostic utility of [89Zr]girentuximab extends beyond the identification of clear cell histology. While the primary trial focused on clear cell renal cell carcinoma, the researchers found that the tracer also identified various forms of non-clear cell renal cell carcinoma (nccRCC). This expanded detection is possible because many aggressive forms of non-clear cell renal cell carcinoma express carbonic anhydrase IX (CAIX) as a result of the tumor microenvironment. In these non-clear cell variants, CAIX expression is fundamentally linked to a hypoxic state, where low oxygen levels within the tumor trigger the production of the protein even in the absence of the genetic VHL mutations typically seen in clear cell cases.

The reanalysis specifically demonstrated that the tracer identified subtypes of papillary renal cell carcinoma (pRCC) that exhibited higher levels of CAIX expression. This was quantified using the H score (a histological method for quantifying protein expression by combining the intensity of staining with the percentage of positive cells). Furthermore, these cases of papillary renal cell carcinoma were characterized by higher PET avidity, measured by the SUVmax (the maximum standardized uptake value, a metric representing the highest intensity of radiotracer concentration within a specific lesion). The clinical performance of [89Zr]girentuximab in this broader context remains robust, providing clinicians with high diagnostic certainty when evaluating indeterminate masses. The findings show a positive predictive value of 98% for any renal malignancy, meaning that a positive PET scan is nearly definitive for the presence of cancer regardless of the specific subtype. For the detection of these malignancies, the tracer demonstrated a sensitivity of 82% and a specificity of 87%. These data suggest that the application of [89Zr]girentuximab PET may significantly influence the management of non-clear cell renal cell carcinoma by providing a non-invasive means to identify aggressive, hypoxic tumors that require prompt intervention.

Clinical Performance and Management Implications

The secondary analysis of the ZIRCON trial data establishes that the diagnostic utility of [89Zr]girentuximab extends significantly beyond the identification of clear cell histology. When evaluating the tracer's ability to detect any form of renal malignancy, the researchers reported a positive predictive value of 98%. This high level of diagnostic certainty indicates that a positive PET scan is nearly definitive for the presence of cancer, providing clinicians with a reliable tool for assessing indeterminate primary renal masses. Furthermore, the tracer demonstrated a sensitivity of 82% and a specificity of 87% for identifying any renal malignancy, maintaining robust performance across diverse histological subtypes. For the practicing physician, these statistics offer a level of confidence that may reduce the reliance on invasive diagnostic procedures.

These findings suggest that [89Zr]girentuximab has clinical applications beyond the detection of clear cell renal cell carcinoma in primary renal masses. By identifying aggressive, hypoxic tumors that express carbonic anhydrase IX, the tracer provides critical diagnostic information that may have significant implications for the management of non-clear cell renal cell carcinoma. For clinicians, this means the imaging agent can assist in the broader screening and stratification of patients with renal lesions, potentially reducing the need for invasive biopsies in cases where the positive predictive value for malignancy is exceptionally high. The ability to non-invasively characterize the molecular profile of a mass allows for more tailored treatment planning and informed surgical decision-making, ensuring that patients with aggressive non-clear cell variants are identified and treated with appropriate urgency.

References

1. Jóźwik−Plebanek K, Saracyn M, Kołodziej M, et al. Theranostics in Renal Cell Carcinoma—A Step Towards New Opportunities or a Dead End—A Systematic Review. Pharmaceuticals. 2024. doi:10.3390/ph17121721

2. Gao B, Kanabur P, Campi R, et al. ‘ BJUI Clinical Dilemma’: the incidental small renal mass in a solitary kidney. British Journal of Urology. 2025. doi:10.1111/bju.16627

3. Kanabur P, Su ZT, Kaba A, et al. Cost-Effectiveness of Incorporating [⁸⁹Zr]Zr-Girentuximab Positron Emission Tomography-Computed Tomography for Characterizing Small Renal Masses.. The Journal of urology. 2026. doi:10.1097/JU.0000000000004912

4. Al-Khanaty A, Qin S, Delgado C, et al. Nuclear Imaging in Renal Cell Carcinoma: Current Evidence and Clinical Applications. Cancers. 2026. doi:10.3390/cancers18020195

5. Oostenbrugge TV, Mulders P. Targeted PET/CT imaging for clear cell renal cell carcinoma with radiolabeled antibodies: recent developments using girentuximab.. Current opinion in urology. 2021. doi:10.1097/MOU.0000000000000872

6. Shuch B, Pantuck AJ, Bernhard J, et al. [⁸⁹Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial.. The Lancet. Oncology. 2024. doi:10.1016/S1470-2045(24)00402-9

7. Hekman MCH, Rijpkema M, Aarntzen EH, et al. Positron Emission Tomography/Computed Tomography with ⁸⁹Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion.. European urology. 2018. doi:10.1016/j.eururo.2018.04.026